Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

GMI 1359

Drug Profile

GMI 1359

Alternative Names: GMI-1359

Latest Information Update: 26 Apr 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator GlycoMimetics
  • Class Antineoplastics; Small molecules
  • Mechanism of Action CXCR4 receptor antagonists; E-selectin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Osteosarcoma
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Acute myeloid leukaemia; Osteosarcoma
  • No development reported Breast cancer; Cancer

Most Recent Events

  • 26 Apr 2023 GMI 1359 is available for licensing as of 26 Apr 2023. https://www.sec.gov/ix?doc=/Archives/edgar/data/1253689/000155837023004864/glyc-20221231x10k.htm
  • 28 Dec 2022 No recent reports of development identified for phase-I development in Breast-cancer(Late-stage disease, Metastatic disease) in USA (IV, Injection)
  • 31 Aug 2022 GlycoMimetics terminates IND applications of GMI 1359 as of August 2022
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top